These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8138659)
21. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer. Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676 [TBL] [Abstract][Full Text] [Related]
22. An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer. Cooper EH; Forbes MA; Hancock AK; Price JJ; Parker D Br J Cancer; 1989 May; 59(5):797-800. PubMed ID: 2736216 [TBL] [Abstract][Full Text] [Related]
23. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients. Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I J BUON; 2007; 12(4):505-11. PubMed ID: 18067209 [TBL] [Abstract][Full Text] [Related]
24. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Yildiz M; Oral B; Bozkurt M; Cobaner A Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750 [TBL] [Abstract][Full Text] [Related]
25. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. Zhao FL; Hu GD; Wang XF; Zhang XH; Zhang YK; Yu ZS J Int Med Res; 2012; 40(3):859-66. PubMed ID: 22906258 [TBL] [Abstract][Full Text] [Related]
26. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA. Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512 [TBL] [Abstract][Full Text] [Related]
27. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer. Yenisey C; Güner G Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960 [No Abstract] [Full Text] [Related]
28. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen. Kopczyński Z; Thielemann A Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926 [TBL] [Abstract][Full Text] [Related]
29. Serial serum MCA measurements in the follow-up of breast cancer patients. Merimsky O; Inbar M; Hareuveni M; Witenberg B; Wolman Y; Chaitchik S Eur J Cancer; 1991; 27(11):1440-4. PubMed ID: 1835861 [TBL] [Abstract][Full Text] [Related]
30. A new tumor marker MCA in breast cancer diagnosis. Eskelinen M; Tikanoja S; Collan Y Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156 [TBL] [Abstract][Full Text] [Related]
31. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer. Huang P; Lan M; Peng AF; Yu QF; Chen WZ; Liu ZL; Liu JM; Huang SH PLoS One; 2017; 12(9):e0183835. PubMed ID: 28902911 [TBL] [Abstract][Full Text] [Related]
32. A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Bombardieri E; Gion M; Mione R; Dittadi R; Bruscagnin G; Buraggi G Cancer; 1989 Feb; 63(3):490-5. PubMed ID: 2643453 [TBL] [Abstract][Full Text] [Related]
33. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617 [TBL] [Abstract][Full Text] [Related]
34. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan. Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295 [TBL] [Abstract][Full Text] [Related]
35. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645 [TBL] [Abstract][Full Text] [Related]
36. Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study. Stierer M; Rosen HR; Forster E; Moroz C Breast Cancer Res Treat; 1991 Nov; 19(3):283-8. PubMed ID: 1777647 [TBL] [Abstract][Full Text] [Related]
37. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma. Gedik GK; Kiratli PO; Tascioglu B; Aras T Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090 [TBL] [Abstract][Full Text] [Related]
38. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383 [TBL] [Abstract][Full Text] [Related]
39. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320 [TBL] [Abstract][Full Text] [Related]
40. [Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer]. Ammon A; Eiffert H; Alhusen R; Weber M; Rümelin B; Groh E; Bartsch H; Marschner N; Nagel GA; Krieger G Onkologie; 1990 Jun; 13(3):210-4. PubMed ID: 2204009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]